Engineered Extracellular Vesicles for Tumor-Targeted Delivery of Therapeutic siRNA for Lung Cancer Therapy
ACS Biomaterials Science & Engineering · 2025
DOI: 10.1021/acsbiomaterials.5c00434 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2025. Verfasst von Rahmat Asfiya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, Missouri 65212, United States. Hauptthemen laut MEDLINE: RNA, Small Interfering, Extracellular Vesicles, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: School of Medicine, University of Missouri, U.S. Department of Defense.
Abstract (Originalsprache)
RNAi-based technologies offer the potential to treat cancer effectively, but safe and efficient RNA administration remains a barrier to their clinical adoption. In this study, we developed extracellular vesicles (EVs) and a gold nanoparticle (GNP)-based hybrid system for the targeted delivery of therapeutic siRNA. We used siRNA to silence the B7-H4 encoding gene (a B7 family immune checkpoint protein, gene VTCN1). The knockdown of B7-H4 inhibits proliferation, invasion, and migration in cancer cell lines and increases apoptosis levels. The standardized nanocomplex of GNPs and B7-H4 siRNA (GNPs-siRB) was hybridized with EVs by a heat shock technique in the presence of CaCl2 to form the EV-siRB hybrid system. Furthermore, the system's ability to selectively deliver siRNA was examined in two Non-Small Cell Lung Cancer (NSCLC) cell lines, viz., H1299 and A549, as well as in a normal lung fibroblast cell line (MRC9). We found that the standard dose of EV-siRB effectively knocked down B7-H4 in cancer cells H1299 and A549 and their spheroids. However, it was less effective in normal lung cells (MRC9). Finally, we demonstrated the antitumor therapeutic effect of the EV-siRB complex in NSCLC xenograft models. The results from this study highlight the effectiveness of the hybrid EV-siRB system in delivering therapeutic siRNA to tumor cells and open an avenue to explore the efficacy of the system in patient-derived NSCLC and other solid tumor models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Anatomical Sciences, University of Missouri School of Medicine, Columbia, Missouri 65212, United States.
- Lincoln University of Missouri, Jefferson City, Missouri 65101, United States.
- Ellis Fischel Cancer Centre, University of Missouri School of Medicine, Columbia, Missouri 65212, United States.
ORCID-Profile: Akhil Srivastava
Förderung
- School of Medicine, University of Missouri
- U.S. Department of Defense
Zitieren
APA
Asfiya, R., Paramanantham, A., Premnath, R., McCully, G., Yousuf, F., Goetz, G., & Srivastava, A. (2025). Engineered Extracellular Vesicles for Tumor-Targeted Delivery of Therapeutic siRNA for Lung Cancer Therapy. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.5c00434
Vancouver
Asfiya R, Paramanantham A, Premnath R, McCully G, Yousuf F, Goetz G, et al. Engineered Extracellular Vesicles for Tumor-Targeted Delivery of Therapeutic siRNA for Lung Cancer Therapy. ACS Biomaterials Science & Engineering. 2025. doi:10.1021/acsbiomaterials.5c00434
BibTeX
@article{Asfiya2025,
author = {Asfiya, Rahmat and Paramanantham, Anjugam and Premnath, Ragavi and McCully, Grace and Yousuf, Fatimah and Goetz, Gregory and Srivastava, Akhil},
title = {Engineered Extracellular Vesicles for Tumor-Targeted Delivery of Therapeutic siRNA for Lung Cancer Therapy},
journal = {ACS Biomaterials Science & Engineering},
year = {2025},
doi = {10.1021/acsbiomaterials.5c00434}
}
EUVIMED